Skip to main content

Table 4 Survival analyses. LCtot - lung cancer total - lung cancer with and without COPD LCCOPD –lung cancer with COPD. LC –lung cancer with and without COPD

From: Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease

 

PFS

OS

PFS histology

OS histology

Protein

LC tot

LC

LCCOPD

LC tot

LC

LCCOPD

SQCC

AC

SQCC

AC

OPG

ns

ns

p = 0.01 HR = 0.17 [0.04–0.70]

ns

ns

p = 0.03 HR = 0.14 [0.03–0.8]

p = 0.02 HR = 0.19 [0.05–0.75]

ns

p = 0.03 HR = 0.16 [0.03–0.81]

ns

PTX3

ns

ns

p = 0.01 HR = 1.70 [1.11–2.61]

ns

ns

ns

ns

ns

ns

ns

vWF

ns

ns

ns

ns

ns

ns

p = 0.05 HR = 3.14 [1.01–9.78]

ns

p = 0.01 HR = 7.68 [1.69–34.77]

ns

ePCR

ns

ns

ns

ns

p = 0.01 HR = 0.29 [0.11–0.77]

ns

ns

ns

ns

ns

PARC

p = 0.01 HR = 1.93 [1.16–3.22]

ns

ns

ns

ns

ns

ns

ns

ns

ns

Cats

ns

ns

ns

ns

ns

ns

ns

ns

ns

p = 0.01 HR = 39.44 [2.27–684.2]

sTNFR1

p = 0.03 HR = 0.57 [0.35–0.94]

ns

p = 0.03 HR = 0.49 [0.25–0.93]

p = 0.01 HR = 0.45 [0.25–0.83]

p = 0.04 HR = 0.3 [0.09–0.95]

p = 0.01 HR = 0.33 [0.15–0.73]

ns

p = 0.01 HR = 0.37 [0.18–0.78]

p = 0.02 HR = 0.31 [0.11–0.85]

p = 0.001 HR = 0.24 [0.10–0.58]

CRP

ns

ns

ns

p = 0.002 HR = 1.41 [1.13–1.75]

p = 0.01 HR = 1.73 [1.14–2.63]

p = 0.17 HR = 1.59 [1.09–2.33]

ns

p = 0.03 HR = 1.39 [1.04–1.85]

p = 0.02 HR = 1.61 [1.08–2.40]

p = 0.01 HR = 1.6 [1.11–2.34]

  1. Legends: Multivariate Cox regression analyses were conducted for the whole lung cancer group, and for subgroups including lung cancer with COPD, lung cancer without COPD, squamous cell carcinomas and adenocarcinomas
  2. We adjusted for explanatory variables like packyear, histology, gender, age, and stage
  3. OS overall survival, PFS progression free survival, HR [] Hazard Ratio with 95% confident interval